DadFinStart your free week
DadFin › Stocks › Healthcare › TLSI

TriSalus Life Sciences, Inc. (TLSI) stock score

Healthcare · Medical Devices · United States

$4.06 ▼ -1.69% today

49.6
Dad Score, out of 100
middling

TriSalus Life Sciences, Inc. (TLSI) is a Medical Devices company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 49.6 out of 100 on the Dad Score, a middling reading that places the business ahead of 50% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #421 of 974. Its strongest axes are price action, risk and conviction; its weakest are valuation and liquidity.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Average
Growth
Average
Price action
Above average
Risk
Above average
Conviction
Above average
Liquidity
Below average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-17.3×
Dividend yield0.00%
Return on capital-141.3%
Operating margin-86.0%
Revenue growth (YoY)+53.4%
FCF yield-6.8%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change-6.7%
Market cap$266M
Next earningsNov 12, 2026

What subscribers see on TLSI

Start your free weekSubscriber? Open the full research →

Medical Devices peers

StockCompanyDad ScoreBandMarket cap
ABTAbbott Laboratories78.9good$169.8B
MDTMedtronic plc90.4strong$110.5B
SYKStryker Corporation86.0strong$105.6B
BSXBoston Scientific Corporation94.3strong$61.7B
EWEdwards Lifesciences Corporation49.4middling$49.0B
DXCMDexCom, Inc.82.9good$32.2B
GEHCGE HealthCare Technologies Inc.94.5strong$29.2B
PHGKoninklijke Philips N.V.62.3middling$23.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.